-+ 0.00%
-+ 0.00%
-+ 0.00%
Kyoto iCAP fund invests additional JPY 300 million in Orizuru Therapeutics
Share
Listen to the news
Kyoto iCAP fund invests additional JPY 300 million in Orizuru Therapeutics
  • Kyoto University Innovation Capital’s KYOTO-iCAP2 fund made an additional equity investment of about JPY 300 million in Orizuru Therapeutics.
  • Orizuru develops iPS cell-derived therapies, including a pancreatic islet cell sheet for type 1 diabetes.
  • Orizuru’s OZTx-410 is in a physician-led safety trial at Kyoto University Hospital, with patient transplants starting in April 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyoto University Innovation Capital Co Ltd published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending